Clinical trial
Dose Response to Recombinant Factor VIIa When Administered for Bleed
NCT00104455 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00104455 |
|---|---|
| Title | Dose Response to Recombinant Factor VIIa When Administered for Bleed |
| Official title | Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy… |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Healthy |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 64 |
| Start date | Jun 1, 2004 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Mar 1, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: